Arylbenzazepines are potent modulators for the delayed rectifier K+ channel: A potential mechanism for their neuroprotective effects

PLoS ONE

Volumn 4, Issue 6, 2009, Pages

  Chen, Xue Qin ^a   Zhang, Jing ^a   Neumeyer, John L ^b   Jin, Guo Zhang ^a   Hu, Guo Yuan ^a   Zhang, Ao ^a   Zhen, Xuechu ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

^b MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 6 CHLORO 2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 3 METHYL 1 (3 METHYLPHENYL) 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; BENZAZEPINE DERIVATIVE; DELAYED RECTIFIER POTASSIUM CHANNEL; DOPAMINE RECEPTOR; POTASSIUM CHANNEL; DOPAMINE RECEPTOR STIMULATING AGENT; NEUROPROTECTIVE AGENT; POTASSIUM CHANNEL BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG MECHANISM; DRUG STRUCTURE; ENANTIOMER; HIPPOCAMPUS; IC 50; NEUROPROTECTION; NONHUMAN; POTASSIUM CURRENT; RAT; STRUCTURE ANALYSIS; VOLTAGE CLAMP; ANIMAL; METABOLISM; NERVE CELL; NEWBORN; PATCH CLAMP; SPRAGUE DAWLEY RAT;

RATTUS;

2,3,4,5-TETRAHYDRO-7,8-DIHYDROXY-1-PHENYL-1H-3-BENZAZEPINE; ANIMALS; ANIMALS, NEWBORN; BENZAZEPINES; DOPAMINE AGONISTS; HIPPOCAMPUS; INHIBITORY CONCENTRATION 50; NEURONS; NEUROPROTECTIVE AGENTS; PATCH-CLAMP TECHNIQUES; POTASSIUM CHANNEL BLOCKERS; POTASSIUM CHANNELS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, DOPAMINE;

EID: 67149118915     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0005811     Document Type: Article

References (35)

1. Arnt J, Hyttel J, Sanchez C (1992) Partial and full dopamine D1 receptor agonists in mice and rats: relation between behavioural effects and stimulation of adenylate cyclase activity in vitro. Eur J Pharmacol 213: 259-267.
2. Cools AR, Lubbers L, van Oosten RV, Andringa G (2002) SKF 83959 is an antagonist of dopamine D1-like receptors in the prefrontal cortex and nucleus accumbens: a key to its antiparkinsonian effect in animals? Neuropharmacol 42: 237-245.
3. Jin L-Q, Goswami S, Cai G, Zhen XC, Friedman E (2003) SKF83959 selectively regulates phosphatidylinositol-linked D1 dopamine receptors in rat brain. J Neuroche 85: 378-386.
4. Panchalingam S, Undie AS (2001) SKF83959 exhibits biochemical agonism by stimulating [35S]GTP[gamma]S binding and phosphoinositide hydrolysis in rat and monkey brain. Neuropharmacol 40: 826-837.
5. Neumeyer JL, Kula NS, Bergman J, Baldessarini RJ (2003) Receptor affinities of dopamine D1 receptor-selective novel phenylbenzazepines. Eur J Pharmacol 474: 137-140.
6. Deveney AM, Waddington JL (1995) Pharmacological characterization of behavioural responses to SK&F83959 in relation to 'D1-like' dopamine receptors not linked to adenylyl cyclase. Brit J Pharmacol 116: 2120-2126.
7. Gnanalingham KK, Erol DD, Hunter AJ, Smith LA, Jenner P, et al. (1995) Differential anti-parkinsonian effects of benzazepine D1 dopamine agonists with varying efficacies in the MPTP-treated common marmoset. Psychopharmacol (Berl) 117: 275-286.
8. Gnanalingham K K, Hunter AJ, Jenner P, Marsden CD (1995) The differential behavioural effects of benzazepine D1 dopamine agonists with varying efficacies, co-administered with quinpirole in primate and rodent models of Parkinson's disease. Psychopharmacol (Berl) 117: 287-297.
9. Nutt JG, Carter JH, Lea ES, Woodward WR (1997) Motor fluctuations during continuous levodopa infusions in patients with Parkinson's disease. Move Disord 12: 285-292.
10. Waddington J, O'Tuathaigh C, O'Sullivan G, Tomiyama K, Koshikawa N, et al. (2005) Phenotypic studies on dopamine receptor subtype and associated signal transduction mutants: insights and challenges from 10 years at the psychopharmacology-molecular biology interface. Psychopharmacol (Berl) 181: 611-638.
11. Wirtshafter D, Osborn CV (2005) The atypical dopamine D1 receptor agonist SKF 83959 induces striatal Fos expression in rats. Eur J Pharmacol 528: 88-94.
12. 1-like partial receptor agonist. Eur J Pharmacol 558: 98-106.
13. 1 agonists on eye blinking in rats. Behav Pharmacol 18: 745-754.
14. Mannoury la Cour C, Vidal S, Pasteau V, Cussac D, Millan MJ (2007) Dopamine D1 receptor coupling to Gs/olf and Gq in rat striatum and cortex: A scintillation proximity assay (SPA)/antibody-capture characterization of benzazepine agonists. Neuropharmacol 52: 1003-1014.
15. Andringa G, Stoof JC, Cools AR (1999) Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacol 146: 328-334.
16. Clifford JJ, Tighe O, Croke DT, Kinsella A, Sibley DR, et al. (1999) Conservation of behavioural topography to dopamine D1-like receptor agonists in mutant mice lacking the D1A receptor implicates a D1-like receptor not coupled to adenylyl cyclase. Neurosci 93: 1483-1489.
17. Zhen X, Goswami S, Friedman E (2005) The role of the phosphatidyinositol-linked D1 dopamine receptor in the pharmacology of SKF83959. Pharmacol Biochem Behav 80: 597-601.
18. Zhang H, Ma L, Wang F, Chen J, Zhen X (2007) Chronic SKF83959 induced less severe dyskinesia and attenuated L-DOPA-induced dyskinesia in 6-OHDA-lesioned rat model of Parkinson's disease. Neuropharmacol 53: 125-133.
19. Yu Y, Wang JR, Sun PH, Guo Y, Zhang ZJ, et al. (2008) Neuroprotective effects of atypical D1 receptor agonist SKF83959 are mediated via D1 receptor-dependent inhibition of glycogen synthase kinase-3B; and a receptor-independent anti-oxidative action. J Neruochem 104: 946-956.
20. Agnati LF, Leo G, Vergoni AV, Martinez E, Hockemeyer J, et al. (2004) Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res Bull 64: 155-164.
21. Obeso JA, Rodriguez-Oroz M, Marin C, Alonso F, Zamarbide I, et al. (2004) The origin of motor fluctuations in Parkinson's disease: importance of dopaminergic innervation and basal ganglia circuits. Neurology 62: S17-30.
22. Yu SP, Farhangrazi ZS, Ying HS, Yeh CH, Choi DW (1998) Enhancement of outward potassium current may participate in β-amyloid peptide-induced cortical neuronal death. Neurobiol Dis 5: 81-88.
23. Yu S-P, Yeh C-H, Sensi SL, Gwag BJ, Canzoniero LM, et al. (1997) Mediation of neuronal apoptosis by enhancement of outward potassium current. Science 278: 114-117.
24. Pal S, Hartnett KA, Nerbonne JM, Levitan ES, Aizenman E (2003) Mediation of neuronal apoptosis by Kv2.1-encoded potassium channels. J Neurosci 23: 4798-4802.
25. 1-42 -induced cell signaling and functional responses in human microglia. J Neurosci 26: 11652-11664.
26. Huang H, Gao TM, Gong L-W, Zhuang Z-Y, Li X (2001) Potassium channel blocker TEA prevents CA1 hippocampal injury following transient forebrain ischemia in adult rats. Neurosci Lett 305: 83-86.
27. Wei L, Yu SP, Gottron F, Snider BJ, Zipfel, et al. (2003) Potassium channel blockers attenuate hypoxia- and ishemia-induced neuronal death in vitro and in vivo. Stroke 34: 1281-1286.
28. Song MK, Liu H, Jiang HL, Yue JM, Hu GY (2006) Electrophysiological characterization of 14-benzoyltalatisamine, a selective blocker of the delayed rectifier K+ channel found in virtual screening. Eur J Pharmacol 531: 47-53.
29. Hu GY, Biro Z, Hill RH, Grillner S (2002) Intracellular QX-314 causes depression of membrane potential oscillations in lamprey spinal neurons during fictive locomotion. J Neurophysiol 87: 2676-2683.
30. Delpon E, Valenzuela C, Gay P, Franqueza L, Snyders D J, et al. (1997) Block of human cardiac Kv1.5 channels by loratadine: voltage-, time- and use-dependent block at concentrations above therapeutic levels. Cardiovascul Res 35: 341-350.
31. Ahn H, Kim S, Jang H-J, Kim M-J, Rhie D-J, et al. (2007) Open channel block of Kv1.3 by rosiglitazone and troglitazone: Kv1.3 as the pharmacological target for rosiglitazone. Naunyn-Schmiedeberg's Arch Pharmacol 374: 305-309.
32. Redman PT, Jefferson BS, Ziegler CB, Mortensen OV, Torres GE, et al. (2006) A vital role for voltage-dependent potassium channels in dopamine transporter-mediated 6-hydroxydopamine neurotoxicity. Neurosci 143: 1-6.
33. Shieh C-C, Coghlan M, Sullivan JP, Gopalakrishnan M (2000) Potassium channels: molecular defects, diseases, and therapeutic opportunities. Pharmacol Rev 52: 557-594.
34. Wickenden AD (2002) K+ channels as therapeutic drug targets. Pharmacol & Therapeut 94: 157-182.
35. Zaks-Makhina E, Kim Y, Aizenman E, Levitan ES (2004) Novel Neuroprotective K+ Channel Inhibitor Identified by High-Throughput Screening in Yeast. Mol Pharmacol 65: 214-219.